top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hICOS mice
Strain Name C57BL/6-Icostm7(ICOS)Bcgen/Bcgen  Common Name  B-hICOS mice
Background C57BL/6 Catalog number 112105
Aliases 
ICOS, AILIM, CD278, CVID1, inducible T cell costimulator
mRNA expression analysis

from clipboard


Strain specific analysis of ICOS gene expression in wild type (WT) mice and B-hICOS mice by RT-PCR. Mouse Icos mRNA was detectable in thymus of WT mice (+/+) and heterozygous B-hICOS mice (H/+). Human ICOS mRNA was detectable only in heterozygous B-hICOS mice (H/+) but not in WT mice (+/+). The positive band was confirmed to be correct by sequencing.

Protein expression analysis


from clipboard


Strain specific ICOS expression analysis in homozygous B-hICOS mice by flow cytometry. Splenocytes were collected from wild type (WT) mice (+/+) and homozygous B-hICOS mice (H/H) stimulated with anti-CD3ε in vivo and analyzed by flow cytometry with vopratelimab (in house), STIM-003 (in house) and GSK-3359609 (in house). ICOS was detectable in WT mice (+/+) and homozygous B-hICOS mice (H/H) due to the cross-reactivity of antibodies. Human ICOS was exclusively detectable in homozygous B-hICOS mice (H/H) but not in WT mice (+/+).

Mouse spleen CD4/CD8 ICOS expression and proliferation


from clipboard


Mouse spleen CD4/CD8 ICOS expression and proliferation by flow cytometry. Splenocytes from wild type (WT) mice (+/+), heterozygous B-hICOS mice (H/+) and homozygous B-hICOS mice (H/H) were stained by CellTrace Violet staining solution, and incubated for 72h in the presence of anti-mCD3ε, or anti-mCD3ε and anti-mCD28, or anti-mCD3ε and human ICOSL recombinant protein. The expression and proliferation of CD4+ T cells and CD8+ T cells were measured by flow cytometry. Mouse ICOS was detectable in WT mice (+/+) and heterozygous B-hICOS mice (H/+). Human ICOS was exclusively detectable in heterozygous B-hICOS mice (H/+)  and homozygous B-hICOS mice (H/H) but not in WT mice (+/+). The data was obtained from a partner. 

Mouse spleen CD4/CD8 ICOS expression and proliferation

from clipboard


Mouse spleen CD4/CD8 ICOS expression and proliferation by flow cytometry. Splenocytes from wild type (WT) mice (+/+), heterozygous B-hICOS mice (H/+) and homozygous B-hICOS mice (H/H) were stained by CellTrace Violet staining solution, and incubated for 72h in the presence of anti-mCD3ε, or anti-mCD3ε and anti-mCD28, or anti-mCD3ε and human ICOSL recombinant protein. The expression and proliferation of CD4+ T cells and CD8+ T cells were measured by flow cytometry. Mouse ICOS was detectable in WT mice (+/+) and heterozygous B-hICOS mice (H/+). Human ICOS was exclusively detectable in heterozygous B-hICOS mice (H/+)  and homozygous B-hICOS mice (H/H) but not in WT mice (+/+). The data was obtained from a partner. 

Mouse spleen CD4/CD8 ICOS expression and proliferation

from clipboard


Mouse spleen CD4/CD8 ICOS expression and proliferation by flow cytometry. Splenocytes from wild type (WT) mice (+/+), heterozygous B-hICOS mice (H/+) and homozygous B-hICOS mice (H/H) were stained by CellTrace Violet staining solution, and incubated for 72h in the presence of anti-mCD3ε, or anti-mCD3ε and anti-mCD28, or anti-mCD3ε and human ICOSL recombinant protein. The expression and proliferation of CD4+ T cells and CD8+ T cells were measured by flow cytometry. The CD4+ T cells and CD8+ T cells activation in heterozygous B-hICOS mice (H/+) and homozygous B-hICOS mice (H/H) was upregulated by anti-mCD3ε and human ICOSL recombinant protein, similar to the activation by anti-mCD3ε and anti-mCD28. This demonstrates that  introduction of human ICOS in place of its mouse counterpart does not affect T cell activation. The data was obtained from a partner. 

Function assay

from clipboard


ICOS delivers a co-stimulatory signal that is essential both for efficient interaction between T and B cells and for normal antibody responses to T-cell-dependent antigens. Mice homozygous for disruptions in the ICOS gene show reduced basal IgG1 levels and impaired interactions between T and B cells. Immunoglobulin class switching, including production of allergy-mediating IgE, is defective. To determine the physiological function of ICOS/ICOSL, we determined the basal serum levels of IgG1 in wild type (WT) mice and homozygous B-hICOS mice (8-week-old, n=5). The basal serum levels of IgG1 in B-hICOS mice were significantly higher than those in WT mice (A), which may be caused by the humanization of ICOS. We further analyzed serum from WT mice and homozygous B-hICOS mice challenged with T-cell-dependent antigen ovalbumin (OVA), and the presence of OVA-specific IgG1 and IgE was determined by ELISA. The OVA-specific IgG1 (B) and IgE (C) in challenged B-hICOS mice were similar to those in challenged WT mice. The data indicate that the ICOS/ICOSL pathway is functional in B-hICOS mice.